Endogenous mammalian steroid, ENT-03, normalizes glucose levels and reduces body fat in DIO mice
June 30, 2023
Researchers from Enterin Inc. and affiliated organizations presented preclinical data for ENT-03, an endogenous spermine bile acid with PTP1B inhibitory activity, being developed as a therapy to normalize glycemia and reverse obesity.
